Jw Life Science Corp (234080) — Cash Flow Reinvestment Rate
Jw Life Science Corp (234080) has a Cash Flow Reinvestment Rate of 0.25x as of March 2026, reinvesting ₩3.56 Billion (capex ₩3.45 Billion plus investments ₩110.06 Million) from operating cash flow of ₩14.17 Billion. See free cash flow generation of Jw Life Science Corp to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Jw Life Science Corp Cash Flow Reinvestment Rate (2015–2025)
Historical reinvestment intensity for Jw Life Science Corp across 11 annual periods. For the full cash flow conversion analysis, see Jw Life Science Corp cash conversion from operations.
Annual Cash Flow Reinvestment Rate for Jw Life Science Corp (2015–2025)
Year-by-year capital reinvestment analysis for Jw Life Science Corp. See 234080 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.33x | ₩13.43 Billion | ₩40.54 Billion | ₩13.43 Billion | ▼ -0.1% |
| 2024 | 0.33x | ₩16.82 Billion | ₩50.69 Billion | ₩10.31 Billion | ▼ -50.7% |
| 2023 | 0.67x | ₩25.28 Billion | ₩37.57 Billion | ₩8.27 Billion | ▼ -74.0% |
| 2022 | 2.59x | ₩36.54 Billion | ₩14.13 Billion | ₩8.29 Billion | ▲ +297.4% |
| 2021 | 0.65x | ₩19.63 Billion | ₩30.17 Billion | ₩18.98 Billion | ▼ -14.6% |
| 2020 | 0.76x | ₩35.63 Billion | ₩46.75 Billion | ₩15.93 Billion | ▲ +128.3% |
| 2019 | 0.33x | ₩8.10 Billion | ₩24.28 Billion | ₩8.09 Billion | ▲ +20.0% |
| 2018 | 0.28x | ₩10.05 Billion | ₩36.13 Billion | ₩10.04 Billion | ▼ -30.7% |
| 2017 | 0.40x | ₩8.85 Billion | ₩22.05 Billion | ₩8.77 Billion | ▼ -73.8% |
| 2016 | 1.53x | ₩24.65 Billion | ₩16.08 Billion | ₩13.37 Billion | ▲ +70.2% |
| 2015 | 0.90x | ₩23.32 Billion | ₩25.90 Billion | ₩23.14 Billion | — |